Trials / Unknown
UnknownNCT02431403
ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- Pusan National University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Open-labeled, multicenter, phase I/II study of imatinib combined with ESHAP as salvage therapy in relapsed/refractory non-Hodgkin's lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ESHAP-Imatinib | After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib. |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2020-02-01
- First posted
- 2015-05-01
- Last updated
- 2015-05-05
Locations
5 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02431403. Inclusion in this directory is not an endorsement.